Get started

Takeda (Poland)

Asthma-chronic obstructive pulmonary disease overlap syndrome in Poland. Findings of an epidemiological study
2014 · Dorota Brzostek, Marek Kokot · Advances in Dermatology and Allergology · 26
PDF
Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study)
2021 · Halina Cichoż-Lach, Agata Michalak, et al. · Therapeutic Advances in Gastroenterology · 10
PDF
Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerative colitis: results from a multicenter prospective POLONEZ study
2023 · Piotr Eder, Maria Kłopocka, et al. · Therapeutic Advances in Gastroenterology · 8
Effectiveness and safety outcomes after long-term (54 weeks) vedolizumab therapy for Crohn’s disease: a prospective, real-world observational study including patient-reported outcomes (POLONEZ II)
2024 · Ariel Liebert, Maria Kłopocka, et al. · Therapeutic Advances in Gastroenterology · 7
Pharmacological Consequences of Inhaled Drug Delivery to Small Airways in the Treatment of Asthma
2014 · Anna Bodzenta-Łukaszyk, Marek Kokot · Advances in Therapy · 5
Facilitated Subcutaneous Immunoglobulin Treatment Patterns in Pediatric Patients with Primary Immunodeficiency Diseases
2024 · Monika Mach-Tomalska, Anna Pituch-Noworolska, et al. · Immunotherapy · 3
HSD115 Results and Implications of a Red Blood Cell (RBC) and Platelet Transfusion Costing Exercise in Select Countries within Europe and North America
2024 · A Molinari, P Ackermann, et al. · Value in Health · 1
Subcutaneous immunoglobulin 20% (Ig20Gly) treatment regimens in pediatric patients with primary immunodeficiencies – real-world data from the IG TATRY study
2023 · Edyta Heropolitańska-Pliszka, Małgorzata Pac, et al. · Expert Review of Clinical Immunology · 1
PDF
Real-world effectiveness and safety of vedolizumab induction therapy for ulcerative colitis: A prospective nationwide Polish observational study
2023 · Edyta Zagórowicz, Halina Cichoż-Lach, et al. · Advances in Clinical and Experimental Medicine · 1
PDF
P421 Real-world effectiveness and safety of vedolizumab induction therapy for Crohn’s disease in Poland – a prospective, observational POLONEZ II study considering patients reported outcomes
2023 · A Liebert, M Kłopocka, et al. · Journal of Crohn s and Colitis · 1
638P Burden of infection in patients with multiple myeloma and secondary immunodeficiencies: A retrospective cohort study
2022 · J. Richter, C. Anderson-Smits, et al. · Annals of Oncology · 1
P1611: Insights Into Facilitated Immunoglobulin (fscig) Use in Patients With Secondary Immunodeficiency Diseases: Final Results From the Figaro Study
2022 · M. Dimou, M. Speletas, et al. · HemaSphere · 1
EP12.11: Real-World Outcomes of Polish Patients With ALK-Positive NSCLC Treated With Brigatinib: 1-Year Results (ENTIRETY Study)
2026 · K. Stencel, G. Czyżewicz, et al. · Journal of Thoracic Oncology
Clinical Response and Improvement of the Quality of Life, Fatigue, Mood, and Sleep Disturbances During Vedolizumab Induction Therapy in Polish Patients With Moderate‐to‐Severe Ulcerative Colitis or Crohn’s Disease
2026 · Agata Michalak, Iwona Zawada, et al. · Canadian Journal of Gastroenterology and Hepatology
Real-world baseline characteristics and diagnostic path of Polish patients with ALK-positive NSCLC eligible for brigatinib treatment: Interim results from the ENTIRETY study.
2025 · Katarzyna Magdalena Stencel, Grzegorz Czyżewicz, et al. · Journal of Clinical Oncology
PDF
Traitement par immunoglobuline sous cutanée facilitée chez les patients atteints de déficit immunitaire primitif et secondaire : l’étude FIGARO
2022 · M. Borte, L. Hanitsch, et al. · La Revue de Médecine Interne
P1582: Clinical Characteristics and Infection-related Outcomes in Patients With Lymphoid Malignancies With or Without Secondary Immunodeficiencies: Results From a Retrospective Multi-database Study
2022 · M. S. Davids, J. Richter, et al. · HemaSphere
Works count: 18
Citation count: 105
Year
Topic
Type